Nyrada Inc. Stock

NYR

AU0000070195

Biotechnology & Medical Research

Market Closed - Australian S.E. 00:10:29 2026-11-06 EST			5-day change	1st Jan Change
0.4950 ^AUD	+11.24%		+1.02%	-55.80%

10-29	Nyrada Says Five Sites Activated in Phase 2a Clinical Trial of Cardioprotection Drug Candidate	MT
10-15	Nyrada Activates Four Clinical Trial Sites; Shares Up 7%	MT

Last Transcript: Nyrada Inc.

Nyrada Inc. - Special Call

02-04

More transcripts

Managers and Directors: Nyrada Inc.

Manager	Title	Age	Since
James Bonnar CEO	Chief Executive Officer	-	2018-01-31
Alexandra Suchowerska CTO	Chief Tech/Sci/R&D Officer	-	-
Benjamin Evison CTO	Chief Tech/Sci/R&D Officer	-	2019-08-23

Director	Title	Age	Since
John Moore CHM	Chairman	61	2019-07-15
Marcus Frampton BRD	Director/Board Member	46	2019-05-31
James Bonnar BRD	Director/Board Member	-	2025-10-07

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NYRADA INC.	+11.24%	+1.02%	-45.00%	+2,257.14%	76.68M
WUXI APPTEC CO., LTD.	-4.83%	+2.88%	+55.87%	+69.12%	69.4B
ARGENX SE	+0.02%	+1.42%	+12.77%	+75.21%	57.24B
LONZA GROUP AG	-1.34%	+3.53%	+23.22%	+101.58%	57.62B
IQVIA HOLDINGS INC.	+2.62%	-1.17%	+29.37%	+37.84%	43.65B
BEONE MEDICINES AG	+5.09%	+9.53%	+26.62%	+121.44%	44.03B
REVOLUTION MEDICINES, INC.	+8.24%	+1.06%	+224.03%	+767.69%	38.08B
CELLTRION, INC.	-1.86%	+11.46%	+26.67%	+61.40%	36.31B
GENMAB A/S	-2.97%	-6.89%	+91.79%	+74.60%	32.61B
WUXI BIOLOGICS (CAYMAN) INC.	-2.18%	+5.68%	+36.21%	-0.69%	25.47B
Average	+1.40%	+1.09%	+48.16%	+356.53%	40.45B
Weighted average by Cap.	+0.05%	+2.43%	+53.92%	+138.45%

See all sector performances

Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Companyâ€™s lead candidate, Xolatryp, is a small molecule cardio protection and neuroprotection therapy. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). Xolatryp, is also a novel blocker targeting TRPC 3/6/7 ion channels, developed to mitigate secondary brain injury and prevent further brain cell death. The critical role of TRPC 3/6/7 channels in secondary injury has been validated in animal knockout models and through research-grade blockers. Its medical programs include Myocardial Ischemia and Arrhythmia Control, Stroke, and Traumatic Brain Injury.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-11-06	A$0.4950	+11.24%	268,415
26-11-05	A$0.4450	+2.30%	323,665
26-11-04	A$0.4350	-10.31%	129,583
26-11-03	A$0.4850	+7.78%	134,754
26-11-02	A$0.4500	-2.17%	281,271

Delayed Quote Australian S.E.

More quotes

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	123M 84.28M 75.59M 69.08M 63.06M 119M 7.92B 833M 332M 4.23B 316M 310M 13.34B	P/E 2025	-9.91x	P/E 2026	-16.4x
Enterprise Value	114M 78.51M 70.42M 64.36M 58.75M 111M 7.38B 776M 309M 3.94B 295M 288M 12.43B	EV / Sales 2025	19.9x	EV / Sales 2026	51.1x
Free-Float	44.94%	Yield 2025 *	-	Yield 2026	-

10-29	Nyrada Says Five Sites Activated in Phase 2a Clinical Trial of Cardioprotection Drug Candidate	MT
10-15	Nyrada Activates Four Clinical Trial Sites; Shares Up 7%	MT
10-12	Nyrada Receives Supportive FDA Feedback on Heart Protection Drug Candidate	MT
09-30	Nyrada Secures US Patent for Heart Protection Drug Candidate	MT
08-20	Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%	MT
08-17	Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
07-26	Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive	MT
07-05	Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate	MT
06-15	Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion	MT
06-03	Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate	MT
05-20	Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%	MT
05-19	Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%	MT
05-19	Nyrada seeks trading halt	RE

22-07-25	Nyrada : Quarterly Activities Report and Appendix 4C	PU
22-06-05	Nyrada : Brain Injury Program Target Unveiled and Phase I Update	PU
22-04-18	Nyrada : Quarterly Activities Report & Appendix 4C	PU
22-03-01	Nyrada : Presentation to Meet the CEO Life Sciences Edition	PU
22-01-20	Nyrada : Quarterly Activities Report & Appendix 4C	PU

1 day	+11.24%
1 week	+1.02%
Current month	+7.61%
1 month	-5.71%
3 months	-33.11%
6 months	-6.60%
Current year	-55.80%

1 week	0.43	0.5
1 month	0.42	0.55
Current year	0.39	1.44
1 year	0.39	1.44
3 years	0.02	1.44
5 years	0.02	1.44
10 years	0.02	1.44

Nyrada Inc. Stock

Stocks

NYR

AU0000070195

Biotechnology & Medical Research

Valuation: Nyrada Inc.

Chart: Nyrada Inc.

Latest news: Nyrada Inc.

Last Transcript: Nyrada Inc.

Press Releases: Nyrada Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Nyrada Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/9/26	John Moore	Buy	Chairman	1,000,000	0.9142%
2/20/26	Rüdiger Weseloh	Free	Director	600,000	0.5485%
2/20/26	Christopher Cox	Free	Director	600,000	0.5485%

	2025	2026
Net sales	2.4M 1.65M 1.48M 1.35M 1.23M 2.32M 155M 16.28M 6.49M 82.67M 6.19M 6.05M 261M	2.01M 1.38M 1.24M 1.13M 1.03M 1.95M 130M 13.67M 5.45M 69.37M 5.19M 5.08M 219M
Net income	-4.85M -3.33M -2.99M -2.73M -2.49M -4.7M -313M -32.92M -13.13M -167M -12.51M -12.24M -528M	-6.56M -4.51M -4.04M -3.7M -3.37M -6.36M -424M -44.55M -17.76M -226M -16.93M -16.56M -714M
Net Debt	-2.93M -2.02M -1.81M -1.65M -1.51M -2.84M -189M -19.91M -7.94M -101M -7.56M -7.4M -319M	-8.38M -5.77M -5.17M -4.73M -4.31M -8.13M -542M -56.97M -22.72M -289M -21.64M -21.18M -913M

Markets		Quality
Australian S.E.	NYR	Delayed
Deutsche Boerse AG	M62	Delayed